Výsledky vyhledávání - "Adrianna Gipson"

KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Autor: Paula Rodriguez-Otero, Sagar Lonial, Sundar Jagannath, Damian J. Green, Nathan Martin, Maria-Victoria Mateos, Jesus G. Berdeja, Adrianna Gipson, Noopur Raje, Zhihong Yang, Andrea Caia, Gianfranco Pittari

Publikováno v: Blood. 138:4830-4830

Background Patients (pts) with RRMM previously exposed to immunomodulatory agents, proteasome inhibitors (PIs), and anti-CD38 antibodies were reported to have poor outcomes with subsequent therapy, and deep and durable responses were uncommon (Chari

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::30ca9b8a4fa44cd077fcf9ccba34a7b1
https://doi.org/10.1182/blood-2021-147412

Zobrazit plný text záznamu

Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist

Autor: Rebecca L. Blanchard, John Palcza, Jan de Hoon, Kristien Van Dyck, Inge De Lepeleire, William S. Denney, Adrianna Gipson, Steve Vermeersch, Tae H. Han, M. Gail Murphy, Chi-Chung Li, William P. Kennedy, Marleen Depré

Publikováno v: British Journal of Clinical Pharmacology. 79:831-837

Aims Calcitonin gene related peptide (CGRP) receptor antagonists are effective acute migraine treatments. A capsaicin-induced dermal vasodilatation (CIDV) model has been developed to provide target-engagement information in healthy volunteers. In the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3b28b6a5e409e96cba6a08f8587cc077
https://doi.org/10.1111/bcp.12547

Zobrazit plný text záznamu

Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea

Autor: John A. Wagner, Meir H. Kryger, John Palcza, Matthew D. Troyer, Hong Sun, Deborah Card, Christopher Lines, Adrianna Gipson, Russell Rosenberg

To investigate the respiratory effects of suvorexant, an orexin receptor antagonist for treating insomnia, in patients with obstructive sleep apnea (OSA).This was a randomized, double-blind, placebo-controlled, 2-period (4 days per period), crossover

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3ccad29392e5a546f843770a08aad8b
https://europepmc.org/articles/PMC4702197/

Zobrazit plný text záznamu

Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors

Publikováno v: Cancer Research. 78:CT180-CT180

Background: CD73 is an ectonucleotidase that converts adenosine monophosphate to adenosine, a potent immunosuppressive soluble mediator that inhibits the cytotoxic function of CD8+ T cells and natural killer cells while promoting proliferation of imm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a106bece84d2f67a395a8031e420695e
https://doi.org/10.1158/1538-7445.am2018-ct180

Zobrazit plný text záznamu

Influence of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics and Pharmacodynamics of Warfarin

Autor: Kenneth C. Lasseter, Eseng Lai, Fang Liu, John A. Wagner, Adrianna Gipson, Mark Stroh, Amy O. Johnson-Levonas, Jules I. Schwartz

Publikováno v: American Journal of Therapeutics. 16:215-223

Laropiprant (LRPT), a prostaglandin D2 receptor 1 antagonist shown to reduce niacin-induced flushing symptoms, is being developed in combination with niacin for the treatment of dyslipidemia. This study assessed the pharmacokinetics/pharmacodynamics

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98706bf68a8e15707cd21adc9f330678
https://doi.org/10.1097/mjt.0b013e31818f9c68

Zobrazit plný text záznamu

KEYNOTE-052: Phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients (pts) with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy

Autor: Rodolfo F. Perini, Guru Sonpavde, Elizabeth R. Plimack, Dean F. Bajorin, Ronald de Wit, Lei Pang, Joaquim Bellmunt, Arlene O. Siefker-Radtke, Holly Brown, Adrianna Gipson, Toni K. Choueiri, Yabing Mai

Publikováno v: Journal of Clinical Oncology. 33:TPS4572-TPS4572

TPS4572 Background: Standard first-line therapy for advanced urothelial cancer is cisplatin-based chemotherapy. Pts who are ineligible for cisplatin therapy, mainly due to renal dysfunction and/or ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3bb04013e4e5e4ac17169f66749fa80d
https://doi.org/10.1200/jco.2015.33.15_suppl.tps4572

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání